These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 37435267)

  • 61. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
    Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
    HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir.
    Lanzafame M; Nicole S; Rizzardo S; Piacentini D; Chiesi S; Lattuada E; Diani E; Carelli M; Vento S; Gibellini D
    New Microbiol; 2018 Oct; 41(4):262-267. PubMed ID: 30311623
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of dolutegravir-based versus efavirenz-based antiretroviral therapy on excessive weight gain in adult treatment-naïve HIV patients at Matsanjeni health center, Eswatini: a retrospective cohort study.
    Mukuna DM; Decroo T; Nyapokoto CM
    AIDS Res Ther; 2024 Jan; 21(1):4. PubMed ID: 38185696
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China.
    Yang X; Fu Y; Xie X; Gan L; Song C; Song Y; Li J; Long H
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1501-1508. PubMed ID: 36168914
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.
    Stellbrink HJ; Reynes J; Lazzarin A; Voronin E; Pulido F; Felizarta F; Almond S; St Clair M; Flack N; Min S;
    AIDS; 2013 Jul; 27(11):1771-8. PubMed ID: 23807273
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of cumulative viraemia following treatment initiation with different antiretroviral regimens: a real-life study in Brazil.
    Pascom AR; Pinho RE; Rick F; Veras NM; Perini FB; Meireles MV; Pereira GF; Benzaken AS; Avelino-Silva VI
    J Int AIDS Soc; 2019 Nov; 22(11):e25397. PubMed ID: 31743620
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
    Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
    Keene CM; Griesel R; Zhao Y; Gcwabe Z; Sayed K; Hill A; Cassidy T; Ngwenya O; Jackson A; van Zyl G; Schutz C; Goliath R; Flowers T; Goemaere E; Wiesner L; Simmons B; Maartens G; Meintjes G
    AIDS; 2021 Jul; 35(9):1423-1432. PubMed ID: 33973876
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
    Hui X; Gan X; Li Q; Sun W
    Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Liver function tests, CD4
    Mengistu EF; Malik DT; Molla MD; Adugna A; Jemal M
    Heliyon; 2024 Jun; 10(12):e33054. PubMed ID: 38988551
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.
    Asare K; Lewis L; van der Molen J; Sookrajh Y; Khubone T; Moodley P; Lessells RJ; Naidoo K; Sosibo P; Garrett N; Dorward J
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad583. PubMed ID: 38045558
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Neuropsychiatric Adverse Events Following Antiretroviral Therapy in People Living with HIV: A Real-World Study of Dynamic Trends and Risk Factors in Hangzhou, China.
    Zhang W; Wang Y; Li E; Yan D; Yu J; Zhu M; Shi J; Zheng L
    Infect Drug Resist; 2023; 16():5007-5019. PubMed ID: 37551279
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
    ; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E
    N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
    BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.